0001193125-21-307948.txt : 20211026 0001193125-21-307948.hdr.sgml : 20211026 20211026160610 ACCESSION NUMBER: 0001193125-21-307948 CONFORMED SUBMISSION TYPE: 8-A12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-A12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 211348408 BUSINESS ADDRESS: STREET 1: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 8-A12B 1 d243510d8a12b.htm 8-A12B 8-A12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

AURA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   32-0271970
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

85 Bolton Street

Cambridge, Massachusetts

   02140
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered

  

Name of each exchange on which
each class is to be registered

Common Stock, par value $0.00001 per share   The Nasdaq Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.  ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐

Securities Act registration statement file or Regulation A offering statement number to which this form relates (if applicable): 333-260156

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 1.

Description of Registrant’s Securities to be Registered.

For a description of Aura Biosciences, Inc.’s (the “Registrant”) common stock, par value $0.00001 per share (the “Common Stock”), to be registered hereunder, reference is made to the information set forth under the heading “Description of Capital Stock” in the Registrant’s prospectus that constitutes a part of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), which information is hereby incorporated by reference. The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act shall be deemed to be incorporated by reference herein.

 

Item 2.

Exhibits.

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

    AURA BIOSCIENCES, INC.
Date: October 26, 2021     By:  

/s/ Elisabet de los Pinos

      Elisabet de los Pinos, Ph.D.
      President and Chief Executive Officer